

1 **Prevalence of COVID-19-related risk factors and risk of severe influenza**
2 **outcomes in cancer survivors: a matched cohort study using linked**
3 **English electronic health records data**

4

5 Helena Carreira*,¹ Helen Strongman*,¹ Maria Peppas,^{2,3} Helen I McDonald,^{2,3}
6 Isabel dos-Santos-Silva,¹ Susannah Stanway,⁴ Liam Smeeth,¹ Krishnan
7 Bhaskaran¹

8 (*equal contribution)

9

10 ¹ Department of Non-communicable Disease Epidemiology, London School of Hygiene and
11 Tropical Medicine, United Kingdom

12 ² Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical
13 Medicine, United Kingdom

14 ³ NIHR Health Protection Research Unit in Immunisation, United Kingdom

15 ⁴ Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey,
16 United Kingdom.

17

18

19

20 **Correspondence to:**

21 Helena Carreira, London School of Hygiene & Tropical Medicine.

22 Keppel Street, WC1 7HT London, UK; Helena.carreira@lshtm.ac.uk

23

24

25

26 Abstract: 247 words

27 Manuscript: 3554 words

1 **Abstract**

2 **Background**

3 People with active cancer are recognised as at risk of COVID-19 complications, but it
4 is unclear whether the much larger population of cancer survivors is at elevated risk.
5 We aimed to address this by comparing cancer survivors and cancer-free controls for
6 (i) prevalence of comorbidities considered risk factors for COVID-19; and (ii) risk of
7 severe influenza, as a marker of susceptibility to severe outcomes from epidemic
8 respiratory viruses.

9 **Methods**

10 We included survivors (≥ 1 year) of the 20 most common cancers, and age, sex and
11 general practice-matched cancer-free controls, derived from UK primary care data
12 linked to cancer registrations, hospital admissions and death registrations. Comorbidity
13 prevalences were calculated 1 and 5 years from cancer diagnosis. Risk of
14 hospitalisation or death due to influenza was compared using Cox models adjusted for
15 baseline demographics and comorbidities.

16 **Findings**

17 108,215 cancer survivors and 523,541 cancer-free controls were included. Cancer
18 survivors had more asthma, other respiratory, cardiac, diabetes, neurological, renal,
19 and liver disease, and less obesity, compared with controls, but there was variation by
20 cancer site. There were 205 influenza hospitalisations/deaths, with cancer survivors at
21 higher risk than controls (adjusted HR 2.78, 95% CI 2.04-3.80). Haematological cancer
22 survivors had large elevated risks persisting for >10 years (HR overall 15.17, 7.84-
23 29.35; HR >10 years from cancer diagnosis 10.06, 2.47-40.93). Survivors of other
24 cancers had evidence of raised risk up to 5 years from cancer diagnosis only (HR 2.22,
25 1.31-3.74).

26 **Interpretation**

27 Risks of severe COVID-19 outcomes are likely to be elevated in cancer survivors. This
28 should be taken into account in policies targeted at clinical risk groups, and vaccination
29 for both influenza, and, when available, COVID-19, should be encouraged in cancer
30 survivors.

31

32 **Funding**

33 Wellcome Trust, Royal Society, NIHR.

34

1 **Research in context**

2

3 **Evidence before this study**

4 Few data are available to date on how COVID-19 affects cancer survivors. We
5 searched PubMed with the keywords “influenza cancer survivors” to identify studies
6 that compared severe influenza outcomes in cancer survivors and in a control group.
7 No study was identified.

8

9 **Added value of this study**

10 In this matched cohort study of routinely collected electronic health records, we
11 demonstrated raised risks of influenza hospitalisation or mortality in survivors from
12 haematological malignancies for >10 years after diagnosis, and in survivors from
13 solid cancers up to 5 years after diagnosis.

14

15 **Implications of all the available evidence**

16 Cancer survivorship appears to be an important risk factor for severe influenza
17 outcomes, suggesting that cancer survivors may also be at raised risk of poor
18 COVID-19 outcomes. This should be taken into account in public health policies
19 targeted at protecting clinical risk groups. Influenza vaccination should be
20 encouraged in this group, and may need to be extended to a wider population of
21 medium- to long-term cancer survivors than currently recommended.

22

1 Introduction

2 As of 7 July 2020, the novel Coronavirus disease 2019 (COVID-19) has been
3 diagnosed in over 11.6 million individuals with more than 539,000 deaths reported
4 worldwide.¹ Around 20% of individuals contracting the virus are estimated to develop
5 severe disease requiring hospitalisation, with a high risk of mortality.² A key aspect of
6 managing the impacts of the pandemic is understanding who is vulnerable to
7 experiencing severe outcomes, so that mitigation strategies can be targeted at those
8 most in need. Those under current treatment for cancer were recognised early on as
9 being a high risk group,³ but the extent to which the much larger population of medium-
10 to long-term cancer survivors, might be considered vulnerable is unknown. In England
11 alone, this group includes over 1.8 million people.⁴

12 Current guidance on who should be considered vulnerable has been largely based on
13 policies developed for previous epidemic respiratory viruses, notably influenza. For
14 example, vaccination against influenza is only recommend for individuals under active
15 treatment for cancer and for up two years following some treatments and
16 haematological cancers,⁵ while longer-term cancer survivors with no recent
17 immunosuppressing treatment are not considered high-risk in vaccination guidance
18 from Public Health England or the American Cancer Society.^{5,6} Yet medium- to long-
19 term cancer survivors could plausibly be at raised risk of severe COVID-19 outcomes.
20 Studies among women with breast cancer have found chemotherapy to be associated
21 with changes in immune parameters that did not return to pre-treatment levels a year
22 or more after end of treatment, raising the possibility of a long-term weakened immune
23 system in cancer survivors.^{7,8} In addition, cancer survivors have known raised risks of
24 heart disease,⁹ which is itself an emerging risk factor for COVID-19 mortality.¹⁰ One
25 large UK study identified raised risks of COVID-19 mortality in survivors of
26 haematological malignancies even several years after cancer diagnosis,¹¹ but there is
27 little other evidence to date to inform policy around managing COVID-19 related risks
28 in cancer survivors.

29 We therefore aimed to investigate whether cancer survivors are likely to be a high-risk
30 group for severe outcomes during the current COVID-19 pandemic in two ways: first,
31 by comparing the prevalence of risk factors currently used to guide COVID-19 policy
32 between site-specific cancers survivors and cancer free controls; second, by
33 comparing the risk of influenza hospitalisation or death between cancer survivors and
34 cancer free controls, as a way of exploring susceptibility to severe outcomes from
35 epidemic respiratory viruses.

36

1 **Methods**

2 This study is reported as per the Strengthening the Reporting of Observational
3 Studies in Epidemiology (STROBE) guideline (S1 Checklist).

5 **Study design and data sources**

6 We carried out a population-based cohort study among 1-year survivors of the 20 most
7 common site-specific cancers matched to cancer-free controls. We used primary care
8 data from Clinical Practice Research Datalink (CPRD GOLD)¹² linked to national data
9 on hospital admissions from the Hospital Episode Statistics Admitted Patient Care
10 (HES APC) database,¹³ cancer registrations from the National Cancer Registration and
11 Analysis Service (NCRAS),¹⁴ death registrations – including cause of death information
12 – from the Office of National Statistics mortality database, and postcode-based index
13 of Multiple Deprivation data.⁹ CPRD GOLD comprises routinely collected clinical and
14 administrative data from general practices in the UK that use Vision software and have
15 chosen to participate; approximately 7% of the UK population is included. Data include
16 Read-coded diagnoses and care events, drug prescriptions, numerical measurements
17 (e.g., height and weight), laboratory test results (e.g. serum creatinine) and health risk
18 factors (e.g. smoking status). Secondary care diagnoses reported to the general
19 practitioner (GP) through discharge letters are typically recorded in the general
20 practice record if they are considered to affect the ongoing care of the patient. Linked
21 International Classification of Diseases, version 10 (ICD-10) coded HES APC and
22 NCRAS data improve ascertainment of diseases treated in secondary care.⁹ Use of
23 linked data restricted our study to England and the study period covered by all linked
24 data sources, January 1 1990 to December 31 2015.

25

26 **Study population**

27 Cohorts of adult cancer survivors (aged ≥ 18 years) were identified for each of the 20
28 most common cancer sites (listed in Table 1), as in a previous study.⁹ Briefly, we used
29 CPRD GOLD, HES APC, and NCRAS to identify 1-year survivors of incident cancer
30 diagnoses. Incident diagnoses were defined as the earliest record of a malignant
31 cancer of interest among individuals with at least 1 year of follow-up meeting CPRD
32 internal quality control criteria prior to the diagnosis (to ensure that the cancer was
33 incident). The derivation of the final analysis cohort is described in Supplementary
34 Figure S1. Cancer survivors with missing data on smoking (5.5%), body mass index
35 (13.0%), or index of multiple deprivation (an area-based proxy for socioeconomic
36 status derived from the patient's postcode; $<0.1\%$) were excluded from the cohorts.

1 Older records were more likely to be excluded, as completeness of lifestyle information
2 improved when the Quality and Outcomes Framework was introduced in 2004.¹²
3 Cancer survivors were followed up from 1 year after diagnosis (index date) and
4 matched on age (± 3 years), sex, and general practice to 5 controls with no history of
5 cancer and at least 2 years of follow-up prior to the index date of the matched cancer
6 survivor (since cancer survivors had to have one year of follow-up before and after the
7 date of cancer diagnosis to be included). Cancer survivors were eligible to be selected
8 as controls until the date of the incident cancer.

9

10 **Outcome and covariates**

11 The main outcome for the study was influenza hospitalisation or death, identified using
12 ICD-10 codes in HES and ICD-9 and ICD-10 codes in ONS mortality data (codes
13 available in Supplementary Table S1). For the primary analysis, we counted
14 hospitalisations with a primary diagnosis of influenza, and deaths with an underlying
15 cause of influenza. In a sensitivity analysis, we broadened the definition to include
16 hospitalisations/deaths with any code for influenza present.

17 Age and sex were matching factors. Other covariates were index of multiple
18 deprivation quintile, smoking status (never, former, current smoker), and common
19 comorbidities identified *a priori* as of potential importance in determining risk of severe
20 COVID-19 outcomes, namely asthma, chronic respiratory disease other than asthma,
21 chronic heart disease, chronic liver disease, chronic neurological disease, chronic
22 kidney disease, diabetes, obesity, sickle cell disease or splenectomy. Other causes of
23 immunosuppression were not included due to overlap with cancer and its treatment. In
24 a secondary analysis we also described the total number of comorbidities (0 vs 1 vs
25 ≥ 2 comorbidities from the aforementioned list). Full variable definitions and code lists
26 are provided in Supplementary Table S1.

27

28 **Statistical analysis**

29 *Prevalence of COVID-19 related risk factors in cancer survivors and controls:* Among
30 cancer survivors and controls alive and under follow-up in CPRD GOLD at the index
31 date (i.e. 1 year after cancer diagnosis for cancer survivors) and 4 years later (5 years
32 after diagnosis), we calculated the proportion with each morbidity of interest for all
33 cancers combined and individual cancer sites. The numerator included those with any
34 history of the relevant comorbidity at the given time point, except for obesity, which
35 was classified based on the most recent body mass index (BMI) measure available at
36 that time point.

1 *Risk of influenza hospitalisation and mortality in cancer survivors and controls:*
2 Individuals were followed up from the index date until the earliest occurrence of the
3 outcome, death without the outcome, or end of study period. Follow-up was not
4 censored at the end of data collection in CPRD GOLD because the main analysis did
5 not require post-baseline primary care data. We then fitted Cox proportional hazards
6 models with time since index date as the timescale, initially accounting only for
7 matching factors (i.e. age at index date, sex, and general practice) through stratification
8 by matched set and then additionally adjusting for the presence of risk factors at the
9 index date (for this analysis obesity was classified at the cancer diagnosis date since
10 weight measures in the year following cancer diagnosis may be unstable). We
11 examined the role of time since cancer diagnosis, by fitting a time-updated variable
12 indicating time of cancer survivorship (1 to <5, 5 to <10, and ≥ 10 years since diagnosis,
13 vs control group patient).

14 Since haematological malignancies directly affect the immune system and treatments
15 may have long-term immune consequences, we stratified results by haematological
16 versus other cancers by fitting a three-level cancer survivorship variable. Due to limited
17 power, we did not break cancer sites down further. In a post hoc analysis, the exposure
18 variable included each haematological malignancy separately (leukaemia, non-
19 Hodgkin lymphoma, multiple myeloma) and four groups of solid cancers (i.e. breast,
20 gastrointestinal, genitourinary, others); Wald tests were used after model estimation to
21 test the null hypothesis of heterogeneity of effect among subgroups.

22 As a secondary analysis, we explored mediation of any raised risk of the primary
23 outcome by development of recognised risk factors during follow-up, by adjusting for
24 time-updated risk factor variables (taking the value “0” until the risk factor is first
25 present, and “1” afterwards). This analysis was additionally censored at the end of
26 follow-up in CPRD GOLD, since it relies on post-baseline primary care data.

27 Patients with missing data on BMI, smoking or deprivation were excluded from the
28 cohorts (see above), therefore all models were based on complete case analyses.
29 Multiple imputation was not used, as the missingness was considered likely to be not
30 at random in the primary care setting^{15,16}, and complete case analysis minimises bias
31 in this situation, providing missingness is conditionally independent of the outcome
32¹⁷. *Sensitivity analyses:* We conducted two main sensitivity analyses. First, we
33 broadened our definition of the outcome to include influenza recorded anywhere in the
34 hospitalisation or death record, to account for the possibility of differential prioritisation
35 of influenza codes between cancer survivors and controls. Second, we adjusted for
36 time-updated influenza vaccination status and ever receipt of a pneumococcal vaccine,
37 as cancer survivors may be more likely to receive influenza and pneumococcal
38 vaccinations than general population controls due to higher engagement with

1 healthcare, or vaccination indicated by immunosuppression following cancer and its
2 treatment, which may protect against influenza and influenza-related death from
3 secondary bacterial pneumonia. Influenza vaccinations were considered current from
4 the date of vaccination until the start of the following influenza season in September.
5 As vaccination records were ascertained from primary care data, these analyses were
6 additionally censored at the end of CPRD follow up; we also re-ran the primary model
7 with this additional censoring in order to provide a similarly censored comparator for
8 the sensitivity and mediation analysis models.

9 *Ethics:* This study was approved by the London School of Hygiene & Tropical Medicine
10 Ethics Committee (LSHTM Ethics Ref: 22416) and the Independent Scientific Advisory
11 Committee for the Medicines and Healthcare products Regulatory Agency database
12 research (20_082). Individual consent was not required for this study. CPRD supplies
13 anonymised data for public health research; individuals are free to opt-out from having
14 their data included in the database.

15 *Role of funding source:* The study funders had no role in study design; in the
16 collection, analysis, and interpretation of data; and in the writing of the article.

17

1 Results

2 This study included 108,215 cancer survivors, of which 9,685 had prior haematological
3 malignancies, and 523,541 individuals with no history of cancer (Table 1). Median
4 (interquartile range [IQR]) age was 67 (58, 76) in the cancer survivor and comparison
5 group; 6,674 (52.4%) and 277,781 (53.1%) of subjects were female, respectively.

6 *Prevalence of COVID-19 related risk factors in cancer survivors and controls*

7 For all cancers combined, we observed higher absolute prevalence of all risk factors
8 for severe COVID-19 except for obesity and sickle cell disease/splenectomy in 1-year
9 cancer survivors, compared to the cancer-free comparison group (Figure 1, sickle
10 cell/splenectomy not shown as the prevalence was <0.2% in all groups). At 5-years
11 after diagnosis, cancer survivors overall had slightly higher prevalence of all risk factors
12 except heart disease and neurological conditions (differences in prevalences ranging
13 from 0.3% for diabetes and chronic liver disease, to 1.8% for chronic kidney disease).
14 Survivors of most site-specific cancers also had raised prevalences of these risk
15 factors, with the magnitude varying by cancer site. The prevalence of obesity was lower
16 in cancer survivors than controls for several cancer sites, but was substantially more
17 common in survivors of uterus and kidney cancers (prevalence difference at 5 years
18 20.1% [95%CI 19.8-20.5], and 8.5% [95%CI 8.1-8.8], respectively). Overall, 62.7% of
19 the cancer survivors had at least 1 of the included comorbidities 5 years after
20 diagnosis, while 37.3% had two or more (Supplementary Table S2). Comorbidity
21 prevalences stratified by age and sex are provided in Supplementary Figure S2(a)-(h).

22 *Risk of influenza hospitalisation and mortality in cancer survivors and controls*

23 205 people had the primary outcome (190 hospitalisations, 15 deaths) during a median
24 follow-up time from the index date of 4.7 years in cancer survivors (IQR 1.9-8.4 years)
25 and 6.2 years in controls (IQR 3.3-9.9 years); follow-up exceeded 10 years for 19,273
26 (18%) cancer survivors and 128,132 (25%) controls. The risk of influenza
27 hospitalization or death was 2.7 times higher (95%CI 2.12-3.44) in cancer survivors
28 compared to people with no history of cancer after accounting for matching factors only
29 (Table 2). Control for other covariates had little impact on the relative risk estimate
30 (adjusted HR=2.78; 95%CI 2.04-3.80).

31 Stratification by cancer group (haematological vs non-haematological) showed
32 substantial differences. Haematological cancer survivors had 15 times higher risk of a
33 severe influenza outcome compared to people without cancer (adjusted HR 15.17;
34 95%CI 7.84-29.35), and further stratifying by time since cancer diagnosis, the hazard
35 ratio was 29.56 (95%CI 10.20-85.66) for those 1 to <5 years from diagnosis, falling to
36 9.56 (95%CI 4.39-20.84) and 10.06 (95%CI 2.47-40.93) for those 5 to <10, and 10+

1 years from diagnosis respectively. Associations were smaller for non-haematological
2 cancer survivors. The overall adjusted HR was 1.38 but compatible with chance
3 variation (95%CI 0.92-2.07). However, stratification by time since diagnosis suggested
4 a doubling of risk in those 1 to <5 years from diagnosis (adjusted HR 2.22, 1.31-3.74)
5 with no raised risk in longer-term survivors.

6

7 *Sensitivity, mediation and post-hoc analyses*

8 Using hospitalisations and deaths with any mention of influenza in the outcome
9 definition led to more events being included (n=320) but a very similar pattern of results
10 to the primary analysis (Supplementary Table S3). In analyses that censored at end of
11 CPRD follow-up, fewer events were included (n=167) but hazard ratios were generally
12 larger than in the primary analysis (overall adjusted HR for cancer survivors vs controls
13 3.88, 2.54-5.91, Supplementary Table S4). Additional control for time-updated
14 exposure to influenza and pneumococcal vaccination led to similar but slightly stronger
15 associations (overall HR 4.06, 2.65-6.24), while adjusting for mediators led to slightly
16 weaker associations (overall HR 3.27, 95%CI 2.12-5.04), but in both cases patterns of
17 results were similar. There was no strong statistical evidence of a variation in the HRs
18 among survivors of leukaemia, non-Hodgkin lymphoma and multiple myeloma
19 (p=0.08), or among survivors from the different solid cancers (p=0.42).

20

1 Discussion

2 Most comorbidities thought to be risk factors for COVID-19 were more prevalent in
3 cancer survivors than cancer-free controls, with variation by cancer site. After
4 accounting for baseline demographics, deprivation, smoking and risk factors
5 distribution, the risks of influenza hospitalisation and death were elevated >9-fold in
6 haematological cancer survivors compared with matched controls for at least 10 years
7 after diagnosis, and >2-fold in non-haematological cancer survivors in the one to five
8 years after diagnosis.

9 To our knowledge, this is the first large cohort study using prospectively collected data
10 to quantify the relative risk of severe influenza outcomes in different groups of cancer
11 survivors compared to the general population, including stratification by time since
12 diagnosis. The few previous studies in this area have reported high rates of influenza
13 among cancer survivors, consistent with our findings, but have lacked a cancer-free
14 comparison group.¹⁸⁻²¹ Hermann et al. investigated outcomes among patients with a
15 history of cancer presenting with influenza, and found no difference in mortality
16 according to haematological or non-haematological cancer type, or activity of the
17 cancer.¹⁸ Our results showed considerably higher risks of hospitalisation or death
18 among haematological cancer survivors, which could be consistent with the findings in
19 Hermann et al. if haematological cancer survivors are at increased risk of infection, but
20 not mortality once infected, compared to non-haematological cancer survivors. Other
21 studies have investigated vulnerability to influenza infection of any severity; two studies
22 using administrative claims data in South Korea found a high rate of claims for
23 influenza among both breast cancer survivors and survivors of childhood cancers.^{19,20}
24 Similarly, Australian survey data found that a large proportion (38%) of hematopoietic
25 stem cell transplant survivors had had influenza-like illnesses in the time (median 5
26 years) since their transplant suggesting potentially high vulnerability to infection, but
27 there was no control group or information on severity of infection.²¹

28 Direct evidence on how COVID-19 affects cancer patients and survivors is immature.
29 Early evidence from China and Italy suggested that patients with history of cancer were
30 overrepresented among those admitted to hospital with COVID-19.^{22,23} The large UK
31 OpenSAFELY study found substantially raised risks of COVID-19 mortality among
32 individuals with prior haematological cancer persisting for at least 5 years from cancer
33 diagnosis, and smaller raised risks for those with a history of non-haematological
34 cancers up to 5 years from diagnosis, consistent with our findings for influenza.¹¹ A
35 study from the COVID-19 and Cancer Consortium (CCC19) reported high 30-day
36 mortality among individuals with laboratory-confirmed COVID-19 and active or

1 previous malignancy, finding high 30-day mortality, even among those in remission,
2 though active disease was a strong predictor of mortality.²⁴ Finally, a study that
3 focussed on patients with active cancer and COVID-19 found a non-statistically
4 significant increased risk of mortality in patients exposed to chemotherapy 4 weeks
5 prior to infection (OR=1.18, 95%CI 0.81-1.72), compared to cancer patients that did
6 not receive chemotherapy, but the small numbers involved require further studies to
7 confirm these associations.²⁵

8 We used a large cohort of cancer survivors and matched controls, nearly a quarter of
9 whom were followed up for more than 10 years. The size of our study enabled us to
10 estimate prevalence of risk factors for severe respiratory infections in site-specific
11 cancer survivors for the twenty most common cancer sites with good precision, and to
12 adjust our primary analysis of severe influenza outcomes for multiple risk factors and
13 stratify by type of cancer (haematological vs other). Multiple validation studies have
14 demonstrated the validity of CPRD primary care data for measuring disease
15 phenotypes including cancer, especially when combined with additional linked data
16 sources.²⁶ Our primary analysis was designed to be specific to hospitalisations and
17 deaths caused by influenza, and a broader definition in sensitivity analysis found
18 similar results. A second sensitivity analysis took account of time-updated vaccination
19 status, which showed that the associations we observed persisted, and in fact were
20 stronger after accounting for this apparent negative confounder.

21 There are some important limitations. We analysed severe influenza in an attempt to
22 inform COVID-19 policy but despite both being infectious respiratory illnesses, it is not
23 certain that risk factors for severe influenza will have the same associations with
24 COVID-19. Our approach follows that of policy makers who have assumed parallels
25 with influenza in the absence of mature COVID-19 data.²⁷ As data from the COVID-19
26 pandemic itself have started to flow, they have largely confirmed a broad overlap
27 between those at high risk for seasonal influenza and for severe COVID-19
28 outcomes.¹¹ Another limitation was that we did not have data on anti-cancer
29 treatments, so could not separate cancer survivors into those under active treatment
30 or not undergoing any treatment, which may be an important determinant of risk. We
31 only included cancer survivors at least one year out from diagnosis, so it is likely that
32 most patients with high-grade malignancies would have completed primary treatment,
33 but people with low-grade tumours could conceivably have received anticancer
34 therapies some years after initial diagnosis, which could explain part of the medium-
35 to long-term increased risk of severe influenza; linked cancer treatment data will be
36 needed to investigate this further. We cannot rule out that differences in the prevalence
37 of risk factors between cancer survivors and controls five years post-diagnosis may be

1 due to increased contact with health services, particularly for diseases such as chronic
2 kidney disease which may be asymptomatic. Our primary outcome combined influenza
3 hospitalisations and deaths but was dominated by the former; it is plausible that there
4 may be a lower threshold for hospitalisation in cancer survivors which could have
5 exaggerated the difference in risk of the primary outcome between cancer survivors
6 and controls, but is unlikely to fully explain the large associations we observed. Finally,
7 we had some missing data on smoking and BMI data, and we excluded those with
8 missing data from the analysis; this is unlikely to affect our findings under the
9 assumption that the association between cancer survivorship and severe respiratory
10 outcomes is the same in people with and without missing data, conditional on the
11 covariates included in the model. We have no reason to doubt this assumption, as
12 recording of BMI and smoking in primary care could be associated with cancer
13 survivorship but most likely is not associated with the risk of influenza hospitalization
14 or death.

15 The high prevalence of several established COVID-19 risk factors in cancer survivors,
16 and the increased risk of influenza hospitalisation and death in survivors of
17 haematological cancers even many years from diagnosis, and in survivors from other
18 cancers in the first five years of survivorship, indicate a likely increased risk of severe
19 COVID-19 outcomes in these patient groups. Early direct evidence from the COVID-
20 19 pandemic appears to be consistent with this. These findings suggest that cancer
21 survivorship should be considered a potentially important risk factor for severe COVID-
22 19 outcomes in public health policy. At present, while UK policy defines those with
23 active cancers and/or receiving treatments as high-risk for COVID-19 complications,
24 the much larger overall population of cancer survivors does not appear in either
25 moderate or high-risk groupings;²⁸ these risk groupings become increasingly important
26 as general population social distancing measures are eased and advice becomes
27 more targeted to those at risk.

28 Our results also have implications for preventive medicine in the coming autumn and
29 winter, when influenza and SARS-CoV-2 are expected to coexist in the population.
30 Improving influenza vaccination coverage among cancer survivors should be a priority,
31 as the vaccine is both effective and safe^{29,30} but coverage has been reported in the
32 range of 50% to 76% among cancer survivors in the US and in the UK.^{31,32}
33 Immunisation for *streptococcus pneumoniae* may also be considered.³³ Of note, UK
34 influenza vaccine guidance focusses on cancer patients with active or recent disease
35 or treatment;⁵ our findings suggest that a broader population of cancer survivors should
36 be considered as a high-risk group for influenza vaccination.

1 Future studies should focus on the risk of severe COVID-19 in cancer survivors,
2 explore the role of comorbidities and prior exposure to specific anti-cancer therapies,
3 disaggregating data by cancer site when possible.

4 In conclusion, survivors of haematological malignancies had substantially elevated
5 risks of influenza hospitalisation or death persisting for at least 10 years after cancer
6 diagnosis, while risk was doubled for survivors of other cancers for up to 5 years from
7 diagnosis. In addition, cancer survivors had higher prevalence of several chronic
8 conditions associated with severe COVID-19, compared to people with no history of
9 cancer. This should be taken into account in public health policies targeted at
10 protecting clinical risk groups. Influenza vaccination should be encouraged in this
11 group, and may need to be extended to a wider population of medium- to long-term
12 cancer survivors than currently recommended.

13

1 **Declaration of Interests**

2 Dr. McDonald reports grants from NIHR Health Protection Research Unit in
3 Immunisation, during the conduct of the study; Dr. Stanway reports personal fees
4 from Roche, personal fees from Eli Lilly, personal fees from Novartis, outside
5 submitted work; Dr. Bhaskaran reports grants from Wellcome Trust, grants from
6 Royal Society, during the conduct of the study; all other authors have no conflicts of
7 interest to disclose.

8

9 **Funding**

10 This work was supported by the National Institute for Health Research (NIHR) Health
11 Protection Research Unit (HPRU) in Immunisation; and the Wellcome Trust and
12 Royal Society (grant no. 107731/Z/15/Z).

13

14 **Data sharing**

15 This study is based in part on data from the Clinical Practice Research Datalink
16 obtained under licence from the UK Medicines and Healthcare products Regulatory
17 Agency. The terms of our licence to access the data preclude us from sharing
18 individual patient data with third parties. The raw data may be requested directly from
19 CPRD following their usual procedures.

20

21 **Acknowledgements**

22 This study is based in part on data from the Clinical Practice Research Datalink
23 obtained under licence from the UK Medicines and Healthcare products Regulatory
24 Agency. The data is provided by patients and collected by the NHS as part of their care
25 and support. The interpretation and conclusions contained in this study are those of
26 the author/s alone. The study was approved by the Independent Scientific Advisory
27 Committee (approval number: 20_082).

28

29 **Contributors**

30 KB, HS and HC designed the study. HS and KB created the data set for a previous
31 study. MP and HMcD created code lists to identify immunisations in the primary care
32 data. HC, HS and KB conducted the analyses in the present study. HC and HS wrote
33 the first draft of the manuscript. All authors revised the manuscript for important
34 intellectual content. HC, HS and KB are guarantors for this study, had access to all
35 study data and accept full responsibility for the work.

36

1 References

- 2 1. Johns Hopkins Coronavirus Resource Centre. COVID-19 Map. 2020.
3 <https://coronavirus.jhu.edu/map.html> (accessed May 2020).
- 4 2. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19.
5 *Lancet* 2020; **395**(10229): 1014-5. doi: 10.1016/S0140-6736(20)30633-4.
- 6 3. Public Health England. Guidance on shielding and protecting people defined
7 on medical grounds as extremely vulnerable from COVID-19. 2020.
8 [https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-](https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19)
9 [extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-](https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19)
10 [extremely-vulnerable-persons-from-covid-19](https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19) (accessed May 2020).
- 11 4. Macmillan Cancer Support and Public Health England's National Cancer
12 Registration and Analysis Service. UK complete cancer prevalence for 2013. Version
13 2.0a April 2017. http://www.ncin.org.uk/about_ncin/segmentation2020).
- 14 5. Public Health England. Influenza - the green book (chapter 19). In: Ramsay
15 M, ed. Immunisation against infectious disease; 2019.
- 16 6. American Cancer Society. Vaccinations and Flu Shots for People with
17 Cancer. [https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-](https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/low-blood-counts/infections/vaccination-during-cancer-treatment.html)
18 [effects/low-blood-counts/infections/vaccination-during-cancer-treatment.html](https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/low-blood-counts/infections/vaccination-during-cancer-treatment.html)
19 (accessed June 2020).
- 20 7. Mozaffari F, Lindemalm C, Choudhury A, Granstam-Bjorneklett H, Lekander
21 M, Nilsson B, Ojutkangas ML, Osterborg A, Bergkvist L, Mellstedt H. Systemic
22 immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and
23 cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study. *Cancer*
24 *Immunol Immunother* 2009; **58**(1): 111-20. doi: 10.1007/s00262-008-0530-5.
- 25 8. Verma R, Foster RE, Horgan K, Mounsey K, Nixon H, Smalle N, Hughes TA,
26 Carter CR. Lymphocyte depletion and repopulation after chemotherapy for primary
27 breast cancer. *Breast Cancer Res* 2016; **18**(1): 10. doi: 10.1186/s13058-015-0669-x.
- 28 9. Padmanabhan S, Carty L, Cameron E, Ghosh RE, Williams R, Strongman H.
29 Approach to record linkage of primary care data from Clinical Practice Research
30 Datalink to other health-related patient data: overview and implications. *Eur J*
31 *Epidemiol* 2019; **34**(1): 91-9. doi: 10.1007/s10654-018-0442-4.
- 32 10. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X,
33 Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and
34 risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a
35 retrospective cohort study. *Lancet* 2020; **395**(10229): 1054-62. doi: 10.1016/S0140-
36 6736(20)30566-3.
- 37 11. Williamson E, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis
38 HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, Mcdonald HI, MacKenna B,

- 1 Tomlinson L, Douglas IJ, Rentsch CT, Mathur R, Wong A, Grieve R, Harrison D,
2 Forbes H, Schultze A, Croker RT, Parry J, Hester F, Harper S, Perera R, Evans S,
3 Smeeth L, Goldacre B. OpenSAFELY: factors associated with COVID-19 death in 17
4 million patients. *Nature* 2020. doi: 10.1038/s41586-020-2521-4.
- 5 12. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T,
6 Smeeth L. Data Resource Profile: Clinical Practice Research Datalink (CPRD). *Int J*
7 *Epidemiol* 2015; **44**(3): 827-36. doi: 10.1093/ije/dyv098.
- 8 13. Herbert A, Wijlaars L, Zylbersztejn A, Cromwell D, Hardelid P. Data Resource
9 Profile: Hospital Episode Statistics Admitted Patient Care (HES APC). *Int J Epidemiol*
10 2017; **46**(4): 1093-i. doi: 10.1093/ije/dyx015.
- 11 14. Henson KE, Elliss-Brookes L, Coupland VH, Payne E, Vernon S, Rous B,
12 Rashbass J. Data Resource Profile: National Cancer Registration Dataset in
13 England. *Int J Epidemiol* 2020; **49**(1): 16-h. doi: 10.1093/ije/dyz076.
- 14 15. Bhaskaran K, Forbes HJ, Douglas I, Leon DA, Smeeth L. Representativeness
15 and optimal use of body mass index (BMI) in the UK Clinical Practice Research
16 Datalink (CPRD). *BMJ Open* 2013; **3**(9): e003389. doi: 10.1136/bmjopen-2013-
17 003389.
- 18 16. Bhaskaran K, Smeeth L. What is the difference between missing completely
19 at random and missing at random? *Int J Epidemiol* 2014; **43**(4): 1336-9. doi:
20 10.1093/ije/dyu080.
- 21 17. White IR, Carlin JB. Bias and efficiency of multiple imputation compared with
22 complete-case analysis for missing covariate values. *Stat Med* 2010; **29**(28): 2920-
23 31. doi: 10.1002/sim.3944.
- 24 18. Hermann B, Lehnert N, Brodhun M, Boden K, Hochhaus A, Kochanek M,
25 Meckel K, Mayer K, Rachow T, Rieger C, Schalk E, Weber T, Schmeier-Jurchott A,
26 Schlattmann P, Teschner D, von Lilienfeld-Toal M. Influenza virus infections in
27 patients with malignancies - characteristics and outcome of the season 2014/15. A
28 survey conducted by the Infectious Diseases Working Party (AGIHO) of the German
29 Society of Haematology and Medical Oncology (DGHO). *Eur J Clin Microbiol* 2017;
30 **36**(3): 565-73. doi: 10.1007/s10096-016-2833-3.
- 31 19. Heo J, Chun M, Oh YT, Noh OK, Kim L. Influenza Among Breast Cancer
32 Survivors in South Korea: A Nationwide Population-Based Study. *In vivo (Athens,*
33 *Greece)* 2017; **31**(5): 967-72. doi: 10.21873/invivo.11155.
- 34 20. Heo J, Jung HJ, Noh OK, Kim L, Park JE. Incidence of Influenza Among
35 Childhood Cancer Survivors in South Korea: A Population-based Retrospective
36 Analysis. *In vivo (Athens, Greece)* 2020; **34**(2): 929-33. doi: 10.21873/invivo.11860.
- 37 21. Dyer G, Gilroy N, Brice L, Kabir M, Gottlieb D, Huang G, Hogg M, Brown L,
38 Greenwood M, Larsen SR, Moore J, Hertzberg M, Tan J, Ward C, Kerridge I. A
39 survey of infectious diseases and vaccination uptake in long-term hematopoietic

- 1 stem cell transplant survivors in Australia. *Transplant infectious disease : an official*
2 *journal of the Transplantation Society* 2019; **21**(2): e13043. doi: 10.1111/tid.13043.
- 3 22. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li
4 S, He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.
5 *Lancet Oncol* 2020; **21**(3): 335-7. doi: 10.1016/S1470-2045(20)30096-6.
- 6 23. Trapani D, Marra A, Curigliano G. The experience on coronavirus disease
7 2019 and cancer from an oncology hub institution in Milan, Lombardy Region. *Eur J*
8 *Cancer* 2020; **132**: 199-206. doi: 10.1016/j.ejca.2020.04.017.
- 9 24. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR,
10 Shete S, Hsu CY, Desai A, de Lima Lopes G, Jr., Grivas P, Painter CA, Peters S,
11 Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya
12 MB, Castellano D, Del Prete SA, Doroshov DB, Egan PC, Elkrief A, Farmakiotis D,
13 Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N,
14 Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C,
15 Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou
16 OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt
17 A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC,
18 Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou
19 AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL, Covid, Cancer C. Clinical
20 impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet* 2020.
21 doi: 10.1016/S0140-6736(20)31187-9.
- 22 25. Lee LYW, Cazier JB, Starkey T, Turnbull CD, Team UKCCMP, Kerr R,
23 Middleton G. COVID-19 mortality in patients with cancer on chemotherapy or other
24 anticancer treatments: a prospective cohort study. *Lancet* 2020. doi: 10.1016/S0140-
25 6736(20)31173-9.
- 26 26. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and
27 validity of diagnoses in the General Practice Research Database: a systematic
28 review. *British journal of clinical pharmacology* 2010; **69**(1): 4-14. doi:
29 10.1111/j.1365-2125.2009.03537.x.
- 30 27. Scientific Advisory Group for Emergencies (UK). Second SAGE meeting on
31 Wuhan Coronavirus - 28 January 2020.
32 [https://www.gov.uk/government/publications/sage-minutes-coronavirus-covid-19-](https://www.gov.uk/government/publications/sage-minutes-coronavirus-covid-19-response-28-january-2020)
33 [response-28-january-2020](https://www.gov.uk/government/publications/sage-minutes-coronavirus-covid-19-response-28-january-2020) (accessed June 2020).
- 34 28. NHS Digital. Coronavirus (COVID-19): Shielded patients list. 2020.
35 <https://digital.nhs.uk/coronavirus/shielded-patient-list> (accessed June 2020).
- 36 29. Blanchette PS, Chung H, Pritchard KI, Earle CC, Campitelli MA, Buchan SA,
37 Schwartz KL, Crowcroft NS, Gubbay JB, Karnauchow T, Katz K, McGeer AJ,
38 McNally JD, Richardson DC, Richardson SE, Rosella LC, Simor A, Smieja M,
39 Zahariadis G, Campigotto A, Kwong JC. Influenza Vaccine Effectiveness Among

- 1 Patients With Cancer: A Population-Based Study Using Health Administrative and
- 2 Laboratory Testing Data From Ontario, Canada. *J Clin Oncol* 2019; **37**(30): 2795-
- 3 804. doi: 10.1200/JCO.19.00354.
- 4 30. Bitterman R, Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici
- 5 L, Paul M. Influenza vaccines in immunosuppressed adults with cancer. *Cochrane*
- 6 *Database Syst Rev* 2018; **2**: CD008983. doi: 10.1002/14651858.CD008983.pub3.
- 7 31. Khan NF, Carpenter L, Watson E, Rose PW. Cancer screening and
- 8 preventative care among long-term cancer survivors in the United Kingdom. *Br J*
- 9 *Cancer* 2010; **102**(7): 1085-90. doi: 10.1038/sj.bjc.6605609.
- 10 32. Stafford KA, Sorkin JD, Steinberger EK. Influenza vaccination among cancer
- 11 survivors: disparities in prevalence between blacks and whites. *J Cancer Surviv*
- 12 2013; **7**(2): 183-90. doi: 10.1007/s11764-012-0257-3.
- 13 33. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M,
- 14 Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I, Infectious Diseases
- 15 Society of A. 2013 IDSA clinical practice guideline for vaccination of the
- 16 immunocompromised host. *Clin Infect Dis* 2014; **58**(3): 309-18. doi:
- 17 10.1093/cid/cit816.
- 18

1 **List of tables**

2 Table 1. Characteristics of the patients included in analyses.

3 Table 2. Relative risk of influenza hospitalisation or death in cancer survivors
4 compared to non-cancer controls.

5

6 **List of figures**

7 Figure 1. Prevalence of factors currently recognised as associated with high risk for
8 severe COVID-19 outcomes in cancer survivors and controls at 1 and 5 years after
9 diagnosis. Sickle cell disease and splenectomy are not presented due to the rarity of
10 the outcome.

11

12 **Supplementary Materials**

13 Supplementary table S1. Definition of the study variables.

14 Supplementary table S2. Number of comorbidities at 1 and 5 years after cancer
15 diagnosis.

16 Supplementary table S3. Results from sensitivity analysis additionally including
17 outcomes where influenza was present but not considered the primary diagnosis in
18 the hospitalization, and/or the primary cause of death.

19 Supplementary table S4. Results from sensitivity and mediation analyses showing
20 the relative risk of influenza hospitalisation or death in cancer survivors compared to
21 cancer-free controls.

22 Supplementary figure S1. Flow chart of people included in the study.

23 Supplementary figure S2. Prevalence of factors currently recognised as associated
24 with high risk for severe COVID-19 outcomes in cancer survivors and controls
25 stratified by age group and sex.

1 **Table 1.** Characteristics of the patients included in analyses.

	Cancer survivors	Comparison group
Number (%)	108,215 (100)	523,541 (100)
Cancer site, N (%)		
Bladder	7,712 (7.13)	-
Breast	25,633 (23.69)	-
Cervix	1,209 (1.12)	-
Central nervous system	906 (0.84)	-
Colorectal	14,216 (13.14)	-
Gastric	1,507 (1.39)	-
Kidney	2,197 (2.03)	-
Leukaemia	3,419 (2.03)	-
Liver	554 (0.51)	-
Lung	5,369 (4.96)	-
Malignant melanoma	7,098 (6.56)	-
Multiple myeloma	1,843 (1.70)	-
Non-Hodgkin lymphoma	4,423 (4.09)	-
Oesophagus	1,794 (1.66)	-
Oral cavity	1,584 (1.46)	-
Ovary	2,710 (2.50)	-
Pancreas	864 (0.80)	-
Prostate	20,709 (19.14)	-
Thyroid	1,028 (0.95)	-
Uterus	3,440 (3.18)	-
Years from index date to end of follow-up		
Mean (SD)	5.7 (4.7)	7.0 (4.7)
Median (IQR)	4.7 (1.9, 8.4)	6.2 (3.3, 9.9)
Range	0.0-24.2	0.0-24.2
Total person-years included (thousands)	620.144	3666.849
Demographics		
Age at index date (years)		
Mean (SD)	66.1 (13.3)	66.0 (13.2)
Median (IQR)	67.0 (58.0, 76.0)	67.0 (58.0, 76.0)
Age at index date (years)		
18-39	4,028 (3.7)	19,208 (3.7)
40-59	27,029 (25.0)	131,049 (25.0)
60-79	60,347 (55.8)	293,080 (56.0)
>=80	16,811 (15.5)	80,204 (15.3)
Gender		
Men	51,541 (47.6)	245,760 (46.9)
Women	56,674 (52.4)	277,781 (53.1)
IMD quintile		
1 (least deprived)	19,334 (17.9)	94,233 (18.0)
2	21,439 (19.8)	103,694 (19.8)
3	20,649 (19.1)	99,684 (19.0)
4	23,114 (21.4)	111,768 (21.3)
5 (most deprived)	23,679 (21.9)	114,162 (21.8)
Previous vaccination at index date		
Influenza	72,924 (67.4)	322,908 (61.7)
Pneumococcal	48,953 (45.2)	224,496 (42.9)

Table 2. Relative risk of influenza hospitalisation or death in cancer survivors compared to non-cancer controls.

	No. of individuals	No. events# (no. deaths)	PY at risk	Associations adjusted for matching factors only*		Associations adjusted for risk factors for severe COVID-19 outcomes, smoking and IMD †	
				HR	95% CI	HR	95% CI
No cancer history	523,541	205 (15)	3,666,849	Ref		Ref	
All cancer survivors	108,215	85 (6)	620,144	2.70	2.12 – 3.44	2.78	2.04 – 3.80
1-5 years since diagnosis	108,215	46 (2)	326,913	4.16	2.94 – 5.88	4.34	2.86 – 6.59
5-10 years since diagnosis	59,938	27 (3)	201,332	2.15	1.44 – 3.21	2.37	1.53 – 3.66
>10 years since diagnosis	24,111	12 (1)	91,899	1.38	0.74 – 2.56	1.37	0.74 – 2.52
By cancer group							
Haematological malignancies	9,685	40 (3)	52,573	12.94	7.47 – 22.44	15.17	7.84 – 29.35
1-5 years since diagnosis	9,685	20 (1)	29,072	22.21	8.34 – 59.17	29.56	10.20 – 85.66
5-10 years since diagnosis	5,131	15 (2)	16,608	8.62	4.00 – 18.58	9.56	4.39 – 20.84
>10 years since diagnosis	1,870	≤5 (0)	6,894	9.90	2.46 – 39.78	10.06	2.47 – 40.93
All other cancers	98,530	45 (3)	567,570	1.50	1.09 – 2.05	1.38	0.92 – 2.07
1-5 years since diagnosis	98,530	26 (1)	297,841	2.47	1.61 – 3.80	2.22	1.31 – 3.74
5-10 years since diagnosis	54,807	12 (1)	184,724	1.05	0.62 – 1.80	1.08	0.58 – 2.01
>10 years since diagnosis	22,241	7 (1)	85,005	0.77	0.34 – 1.73	0.74	0.34 – 1.61


Hospitalisations or deaths with influenza as the primary diagnosis/underlying cause.

* Cancer survivors and non-cancer controls were matched on age (within a 3-year age range), sex and primary care practice.


† Model adjusted for risk factors for poor COVID-19 outcomes (i.e. asthma and other chronic respiratory diseases, chronic neurological diseases, chronic liver disease, chronic heart disease, chronic kidney disease, sickle cell disease or splenectomy, diabetes and obesity), smoking (former vs. current vs. never smokers), and quintiles of relative deprivation measured by patient-postcode linked Index of Multiple Deprivation.

HR = Hazards ratio; PY = person-years at risk; Ref = reference category.


Asthma




Other chronic respiratory disease



Chronic liver disease




Chronic kidney disease




1 year CS
 1 year GPC
 5 year CS
 5 year GPC

— CS > GPC (reasonable evidence)
 — GPC > CS (reasonable evidence)
 — weak evidence or no difference


Diabetes




Obesity



Chronic heart disease



Chronic neurological conditions



1 year CS
 1 year GPC
 5 year CS
 5 year GPC

— CS > GPC (reasonable evidence)
 — GPC > CS (reasonable evidence)
 — weak evidence or no difference